Drug Profile
Research programme: antibody therapeutics - Agenus/4-Antibody
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator 4-Antibody
- Developer Agenus; Redbiotec
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Undefined in Switzerland
- 13 Feb 2014 4-Antibody has been acquired by Agenus
- 17 Feb 2012 Early research in Undefined indication in Switzerland (unspecified route)